Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT04645212
Active, not recruiting Observational

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212 · tracked via the Priya Life Science USA tracker
Sponsor
Adverum Biotechnologies, Inc
Phase
Observational
Started
2020-12-14
Last updated
2026-02-10

Condition(s) studied

Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration

Investigational drug(s) / intervention(s)

ADVM-022

ADVM-022: Long term follow-up of subjects that received ADVM-022

Study summary

ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants who received a single dose of ADVM-022 at any dose in the OPTIC study * Willing and able to provide informed consent Exclusion Criteria: * None

Primary outcome measure(s)

  • Severity and incidence of ocular and systemic adverse events (AEs). — 416 weeks (8 years)
    Severity and incidence of ocular and systemic adverse events

Trial sites (9)

FacilityCityRegionStatus
Adverum Clinical Site Bakersfield California
Adverum Clinical Site Beverly Hills California
Adverum Clinical Site Lakewood Colorado
Adverum Clinical Site Deerfield Beach Florida
Adverum Clinical Site Reno Nevada
Adverum Clinical Site Philadelphia Pennsylvania
Adverum Clinical Site Nashville Tennessee
Adverum Clinical Site Bellaire Texas
Adverum Clinical Site The Woodlands Texas

More Adverum Biotechnologies, Inc. trials in the USA

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) Recruiting
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] Active, not recruiting
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) Active, not recruiting
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration Recruiting
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration Active, not recruiting

Other trials for the same condition

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration Active, not recruiting
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Active, not recruiting
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy Enrolling by invitation
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04645212 on ClinicalTrials.gov ↗ ← All trials in the USA